Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Is Slipping Today

By Keith Speights – Aug 10, 2021 at 11:24AM

Key Points

  • Bank of America analyst Geoff Meacham stated that Moderna's shares are priced at a "ridiculous" level.
  • Moderna's market cap is now greater than those of several other drugmakers generating higher revenue.
  • The key for Moderna to continue its success will be to secure supply deals for 2022 and beyond.

Motley Fool Issues Rare “All In” Buy Alert

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An analyst thinks the vaccine stock is ridiculously overpriced.

What happened

Shares of Moderna (MRNA 1.10%) were slipping 5.8% as of 10:52 a.m. EDT on Tuesday. The decline came after Bank of America analyst Geoff Meacham wrote to investors that the stock's valuation has gone "from unreasonable to ridiculous." Meacham reiterated an underperform rating for Moderna with a price target of $115, roughly 75% below the current price of the biotech's shares. 

So what

Does one analyst's opinion matter all that much? Not really. However, it's prudent to understand the reasoning behind analysts' views.

Moderna now has a market cap of more than $185 billion with the vaccine stock soaring more than 340% so far this year. That makes Moderna bigger than several biopharmaceutical companies with higher sales and earnings.

A healthcare professional holding a syringe and vaccine vial.

Image source: Getty Images.

Perhaps the most significant concern about Moderna's valuation is the uncertainty over the company's recurring revenue after 2022. There's no guarantee that Moderna's COVID-19 vaccine will be able to rake in as much money going forward as it will over the next year and a half.

Investors who remain bullish about Moderna, though, will likely point to the company's messenger RNA (mRNA) platform and its growing cash stockpile. They think that Moderna will be able to develop or buy additional blockbuster products that could drive growth for a long time to come. 

Now what

While the debate about Moderna's valuation will probably continue, the main thing to watch with the company now is its progress in securing additional supply deals. Moderna said in its second-quarter update that it already has 2022 supply agreements worth around $12 billion with options of around $8 billion. 

Bank of America is an advertising partner of The Ascent, a Motley Fool company. Keith Speights owns shares of Bank of America. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
MRNA
$178.34 (1.10%) $1.94

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.